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a b s t r a c t
ABC transporter overexpression is an important mechanism of multidrug resistance (MDR) and one of the
main obstacles to successful cancer treatment. As these proteins actively remove chemotherapeutics from
the tumor cells, the pharmacological inhibition of their activity is a possible strategy to revert drug
resistance. Moreover, the ability of MDR inhibitors to sensitize resistant cells to conventional drugs is
important for their clinical use. Evidence has shown that the multidrug resistance protein 1 (MRP1/ABCC1)
is a negative prognostic marker in patients with lung, gastric, or breast cancers or neuroblastoma. Previous
data have shown that 3β-acetyl tormentic acid (3ATA) inhibits the transport activity of the protein MRP1/
ABCC1. In this study, we evaluated the ability of 3ATA to sensitize an MDR cell line (GLC4/ADR), which
overexpresses MRP1, and investigated the anti-MRP1 mechanisms activated by 3ATA. The results showed
that 3ATA is able to reverse the resistance of the MDR cell line to doxorubicin and vincristine, two drugs
that are commonly used in cancer chemotherapy. Regarding the sensitizing mechanism induced by 3ATA,
this work shows that the triterpene does not modulate the expression of MRP1/ABCC1 but is able to
reduce total intracellular glutathione (GSH) levels and decrease the activity of glutathione-s-transferase
(GST), the enzyme responsible for the glutathione conjugation of xenobiotics. Together, these results show
that 3ATA sensitizes the MDR cell line overexpressing MRP1/ABCC1 to antineoplastic drugs and that this
effect is mediated by the modulation of intracellular levels of GSH and GST activity.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Multidrug resistance (MDR) plays a crucial role in the failure of
cancer chemotherapy and relapses in patients after treatment.
Although MDR is a multifactorial process, the most investigated of
its mechanisms is the efﬂux of drugs by one or more energy-
dependent transporters, such as glycoprotein P (P-gp/ABCB1),
multidrug resistance protein 1 (MRP1/ABCC1) and breast resis-
tance protein (Wu et al., 2011; Tiwari et al., 2011).
MRP1/ABCC1 is primarily an active transporter of glutathione
(GSH), glucuronate or sulfate-conjugated organic anions (Cole
and Deeley, 2006), although it can also transport unconjugated
substrates (Rothnie et al., 2008). In cancer cells, MRP1/ABCC1 may
export GSH or use this compound for the transport of xenobiotics,
including antineoplastic drugs such as vincristine (VCR) (Loe et al.,
1998; Mao et al., 2000) and doxorubicin (DOX) (Jedlitschky et al.,
1996; Priebe et al., 1998; Sugiyama and Sadzuka, 2003). Glu-
tathione conjugation, which is carried out by the glutathione-s-
transferases (GSTs) (Laborde, 2010), is an important step in the
cellular detoxiﬁcation of several compounds, including cytotoxic
drugs (Board and Menon, 2013). Most of the drug resistant cells
that overexpresses MRP1/ABCC1 and/or GST maintain an elevated
intracellular pool of GSH, thereby ensuring that the intracellular
concentration of the antineoplastic drug will be maintained at a
lower level than that necessary for cytotoxicity (van Brussel et al.,
2004; Takemura et al., 2001; Gallego et al., 2004). Because GSH is
an essential component of cellular antioxidant systems, maintain-
ing redox homeostasis, this molecule is part of the cellular defense
against Reactive Oxygen Species (ROS). Changes in the GSH pool
may generate an imbalance between oxidative and antioxidant
molecules that can lead to the accumulation of Reactive Oxygen
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Species, which are produced in the cells. High levels of Reactive
Oxygen Species, in turn, can cause damage to macromolecules,
inducing cell death (Trachootham et al., 2009).
The expression of MRP1/ABCC1 is a negative prognostic marker
in patients with several types of cancer (Deeley et al., 2006; Chen
et al., 2011; Xu et al., 2010). This protein is overproduced in glioma
cell lines and in vivo samples, its levels increase with the grade of
the tumor (Declèves et al., 2006). The use of inhibitors to block the
function or expression of ABC proteins is one of the strategies used
to overcome the resistance mediated by MRP1/ABCC1 and other
ABC proteins (Lee, 2010). Nevertheless, most likely due to the
complexity of its mechanism of transport, the number of selective
modulators of MRP1/ABCC1 is small, and none has been exten-
sively studied in clinical trials. Therefore, novel compounds with
low toxicity and high efﬁcacy in reversing the resistance mediated
by MRP1 are urgently needed. In previous studies (Rocha et al.,
2007, 2012a, 2012b), we showed that the pentacyclic triterpene,
3β-acetyl tormentic acid (3ATA), is cytotoxic to different neoplastic
cell lines, inhibits the transporter activity of various members of
the MRP/ABCC family and is more efﬁcient in modulating MRP1/
ABCC1 activity. The present study investigates whether 3ATA
sensitizes a multidrug-resistant cell line overexpressing MRP1/
ABCC1 to antineoplastic drugs and probes mechanisms involved in
this modulatory effect.
2. Materials and methods
2.1. Chemicals
3β-acetyl tormentic acid (MW 531.71) at 97% purity, isolated
from Cecropia lyratiloba using countercurrent chromatography
(Oliveira et al., 2005), was dissolved in dimethyl sulfoxide (DMSO,
Sigma, St. Louis, MO, USA and diluted in culture media (Rocha et al.,
2007). MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide), BSO (L-buthionine (S,R)-sulfoximine), doxorubicin, vin-
cristine and anti-βactin antibody were also purchased from Sigma.
Cisplatin was acquired from Zodiac (São Paulo, Brazil). MK-571 was
obtained from Enzo Life Sciences (Farmingdale, NY, USA). The anti-
MRP1 monoclonal antibody (clone QCRL-2) and goat anti-mouse
IgG-FITC secondary antibody were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The anti-MRP1 antibody, clone
MRPr1, was purchased from Alexis Biochemicals (San Diego, CA).
Annexin V-FITC apoptosis detection Kit was purchased from R&D
Systems USA). H2DCFDA (20,70-dichlorodihydroﬂuorescein diace-
tate) was purchased from Molecular Probes (Eugene, OR, USA).
GSH and GST colorimetric assay kits were purchased from BioVision
(Mountain View, CA). 5-carboxyﬂuorescein diacetate (5-CFDA) was
obtained from Calbiochem (San Diego, CA, USA).
2.2. Cell lines
GLC4, a small-cell lung cancer cell line derived from a pleural
effusion and GLC4/ADR, a GLC4 derivative cell line, obtained by
stepwise increases in doxorubicin concentrations in the culture
medium (Zijlstra et al., 1987), were used. GLC4/ADR is resistant to
not only doxorubicin but also a wide range of other chemother-
apeutic agents. The doxorubicin resistance in GLC4/ADR is due to
the downregulation of DNA-topoisomerase II (TOPO II) activity and
to the ampliﬁcation and consequent 79-fold overexpression of the
MRP1 gene (de Groot et al., 2007). GLC4/ADR was maintained in
culture medium containing 1.2 mM doxorubicin. GLC4/ADR was
cultured without doxorubicin for 20 days before the experiments.
Cells were cultured at 37 1C under 5% CO2 in the recommended
medium, RPMI 1640 (Life Technologies, Inc., Rockville, MD, USA),
supplemented with heat-inactivated 10% fetal calf serum (FCS, Life
Technologies, Inc., Rockville, MD, USA), 2 mM L-glutamine, 100 U/
ml penicillin and 100 mg/ml streptomycin (Life Technologies, Inc.,
Rockville, MD, USA).
2.3. Cytotoxicity assay
Sensitivities of GLC4 and GLC4/ADR cell lines to various
chemicals were assessed using (% DNA fragmentation evaluation)
cell cycle analysis (DNA fragmentation), Annexin V-FITC/PI
((Annexin V-FITC/PI (apoptotic and necrotic cells)) and MTT assay
(cell viability). After 24 h of resting, plated cells (1104/well)
were treated with various concentrations of 3ATA and/or anti-
tumoral drugs, which were added into the wells and incubated for
a further 48 h. Subsequently, cells were harvested and suspended
in 200 μl of hypotonic ﬂuorescent solution (50 μg/ml propidium
iodide (PI) and 0.1% Triton X-100 in 0.1% sodium citrate buffer) for
cell cycle analysis. After 1 h of incubation in the dark at 4 1C, the
DNA content was measured by ﬂow cytometry (FL-2) (FACS
Calibur, Becton Dickinson, Franklin Lakes, NJ, USA). Data acquisi-
tion and analysis were controlled by Cellquest software version
3.1f. Subdiploid populations were considered apoptotic. For
Annexin V-FITC/PI assay cells were incubated with the R&D
apoptosis detection Kit according to the manufacture instructions,
washed and resuspended in the binding buffer and analysis of
apoptotic and necrotic cells was performed by ﬂow cytometry. For
MTT assay, each well received 2.5 mg/ml of MTT (3-4,5-
dimethylthiazo-2yl-2,5-diphenyltetrazolium bromide), and the
plates were incubated for a further 4 h at 37 1C. The medium
was removed, and the crystals of reduced formazan that had
formed were dissolved in 150 mL of DMSO. The absorbance of each
well was then determined at 570 nm using a microplate reader
(BenchMark, Bio-Rad, CA). The effects of the drug on cell viability
were calculated using cells treated with DMSO as a control.
2.4. MRP1/ABCC1 transport activity and expression assay
The activity of MRP1/ABCC1 was determined based on the
accumulation of speciﬁc substrates using 5-carboxyﬂuorescein
diacetate (CFDA), a non-ﬂuorescent molecule that is converted
into ﬂuorescent carboxy-ﬂuorescein (CF) by intracellular esterases.
Several studies have shown that cells exhibiting high levels of the
ABCC1 protein actively exclude carboxy-ﬂuorescein (CF); CF can
therefore be used as an indicator of MRP1 pump activity (Braga
et al., 2007). For each experiment, cells (1105/well) were seeded
into 24-well plates and pre-incubated for 24 h at 37 1C/5% CO2 to
allow stabilization of the culture. Cells were then incubated for
30 min with medium (autoﬂuorescence) or with 5 μM CFDA in the
presence of medium, 50 μM MK-571 (a commercial inhibitor of
MRP1) or the desired concentrations (6.25, 12.5, 25 or 50 μg/ml) of
3ATA and intracellular ﬂuorescence was evaluated.
Alternatively, cells were incubated with 3ATA for 24 or 48 h
before addition of CFDA. The cells were subsequently washed in
PBS, harvested and maintained in ice until ﬂow cytometry analysis
was performed (FACS Calibur, Beckton–Dickinson cytometer). The
Mean Fluorescence Intensity (MFI) associated with intracellular CF,
which reﬂects the transporter activity of MRP1, was used to
quantify this activity. The results are presented as the mean7S.D.
of arbitrary units of mean ﬂuorescence intensity.
MRP1 expression in GLC4/ADR cells was evaluated using ﬂow
cytometry and western blotting. For the ﬂow cytometry analysis,
after 48 h of treatment with 3ATA, cells were harvested, permea-
bilized with FACS lysing solution (BD Biosciences, San Jose, CA,
USA) for 30 min and incubated with a blocking solution (PBS
supplemented with 5% BFS) for 10 min. The cells were then
centrifuged at 160g/5 min and resuspended in PBS containing
anti-MRP1 antibody (1:100 dilution, clone QCRL-2) for 60 min at
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room temperature. After two washes with PBS, the cells were
incubated with a FITC-labeled goat anti-mouse IgG antibody
(1:200) for 30 min. After washing with PBS, the cells were
resuspended in PBS, and their ﬂuorescence was measured by ﬂow
cytometry (FL-1). The Mean Fluorescence Intensity associated with
MRP1/ABCC1 expression level was used for this quantiﬁcation. For
the western blotting assay, cells (3105) were plated in 6-well
plates and then incubated with medium or 3ATA (12.5 or 25 mg/
ml) 24 h later for a further 48 h. Total cells lysates were prepared
by lysing harvested cells in lysis buffer (50 mM Tris pH 7.4, 0.5%
Nonidet P-40, 1 mM EDTA and 150 mM NaCl; proteases inhibitors
were added at the time of preparation). Samples were fractionated
in an 8% polyacrylamide gel. The proteins were then transferred
onto a nitrocellulose membrane (Bio-Rad Laboratory Inc., Her-
cules, CA, USA), which was blocked for 1 h with Tris-buffered
saline containing 0.1% Tween 20 and 5% milk. The membrane was
then incubated overnight at 4 1C with either anti-MRP1 (MRPr1)
or anti-β-actin antibodies. Following a series of washes with
Tris-buffered saline containing 0.1% Tween 20, a secondary horse-
radish peroxidase antibody was added and incubated for 1 h at
room temperature. After washing, the blot was visualized by
chemiluminescence using the enhanced chemiluminescence
(ECL) system (GE Healthcare, Tokyo) according to the manufac-
turer's instructions.
2.5. Determination of total cellular glutathione content
The 3ATA-mediated modulation of intracellular GSH content
was analyzed using the colorimetric GSH detection kit according
to the manufacturer's instructions (BioVision, Mountain View, CA).
This kit is based on the enzymatic recycling method involving
oxidized glutathione (GSSG) reductase and 2-nitro-5-thiobenzoic
acid (DTNB). Brieﬂy, GLC4/ADR cells (1105 cells/well) were
plated in a 24-well plate; 24 h later, the cells were treated with
25 or 50 mg/ml of 3ATA or 500 mM of BSO, an inhibitor of GSH
synthesis. After a 48-h incubation at 37 1C/5% CO2, the cells
(1106) were harvested, washed with PBS, lysed in ice-cold
GSH buffer and centrifuged at 700g for 5 min at 4 1C. Supernatants
were assayed for total intracellular GSH by mixing with a reduced
form of nicotinamide adenine dinucleotide phosphate generating
mix, glutathione reductase, and GSH reaction buffer. The absor-
bance was determined at 405 nm using a microplate reader, and
the results were expressed as % relative to the control.
2.6. Determination of glutathione-S-transferase activity
3ATA-mediated modulation of glutathione-S-transferase (GST)
activity was analyzed using the GST colorimetric activity assay kit
according to the manufacturer's instructions (BioVision). This kit is
based upon the GST-catalyzed reaction between GSH and the GST
substrate, CDNB (1-chloro-2, 4-dinitrobenzene), which has the
broadest range of isoenzyme detectability (e.g., alpha-, mu-, pi-,
and other GST isoforms, except theta). Brieﬂy, GLC4/ADR cells
(1105 cell/well) were plated into a 24-well plate; 24 h later, the
cells were treated with 12.5, 25 or 50 mg/ml of 3ATA and incubated
for another 24 h at 37 1C/5% CO2. Then, 1106 cells were har-
vested, washed with PBS and sonicated in GST Assay Buffer. After
centrifugation at 10,000g for 15 min at 4 1C, the supernatant was
collected and assayed. The absorbance was measured at 340 nm
once every minute for 5 min using a plate reader, and the results
were expressed as % relative to the control.
2.7. Quantiﬁcation of intracellular Reactive Oxygen Species
Cellular Reactive Oxygen Species were measured using the
ﬂuorogenic reagent 20,70-dichlorodihydro-ﬂuorescein diacetate
(H2DCFDA) (Invitrogen Molecular Probes, Eugene, OR). The
H2DCFDA substrate was intracellularly deacetylated using a non-
speciﬁc esterase and further oxidized by cellular peroxides to
the ﬂuorescent compound, 2,7-dichloroﬂuorescein (DCF) (Ex/Em¼
485 nm/535 nm). GLC4/ADR cells were seeded into 24-well plates
(5104 cells/well) and incubated with medium or various con-
centrations of 3ATA for 24 or 48 h. After treatment, the cells were
washed with PBS and incubated for 15 min in 4 mM H2DCFDA at
37 1C. The cells were then harvested and analyzed using FACS with
ﬂuorescence detection at 530 nm. The ROS concentrations follow-
ing drug treatment were estimated by measuring the change in
mean ﬂuorescence intensity using only live cells, which was
calculated using CellQuest software. For each sample, 10,000
events were collected.
2.8. Statistical analysis.
Results represent the mean of at least three independent
experiments. Instat software (GraphPad Prism 4, San Diego, CA,
USA) was used to analyze the data. One-way analysis of variance
(ANOVA) with post hoc analysis using Bonferroni's multiple
comparisons test was used for parametric data. Statistical signiﬁ-
cance was deﬁned as Po0.05.
3. Results
3.1. 3β-Acetyl tormentic acid decreases cell viability and MRP1/
ABCC1 transport activity but does not interfere with MRP1/ABCC1
expression
Considering the role of MRP1/ABCC1 in cancer drug resistance,
we used the MTT assay to evaluate the cytotoxic effect of 3ATA on
GLC4/ADR, a MDR lung cell line that overexpresses MRP1 (de
Groot et al., 2007). Twenty-four hours after seeding, cells were
treated with various concentrations of 3ATA (Fig. 1), and viability
was measured using MTT 48 h later. The results showed that 3ATA
decreased the viability of this cell line in a dose-dependent
manner and was cytotoxic only at concentrations greater than
25 mg/ml (Fig. 2A).
To evaluate whether 3ATA was able to modulate the activity of
MRP1/ABCC1, cells were loaded with 5-CFDA in the presence of
medium, MK571 or various concentrations of 3ATA, and intracel-
lular ﬂuorescence was evaluated 30 min later. The results showed
that 3ATA enhanced the ﬂuorescent substrate loading in a dose-
dependent manner, thus demonstrating that treatment with this
compound could effectively inhibit the activity of MRP1/ABCC1 in
this cell line (Fig. 2D and E). Cells treated with 12.5 or 25 μg/ml of
3ATA (non-toxic concentrations) retained 2.9 and 4.5-fold more
substrate, respectively, than untreated cells. A dose-dependent
Fig. 1. Chemical structure of 3β-acetil tormentic acid.
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inhibition of MRP1 was also observed in cells incubated with 3ATA
for 24 or 48 h (Fig. 2F).
To assess whether 3ATA was also able to modulate MRP1/
ABCC1 protein expression, cells were treated with 12.5, 25 or
50 mg/ml of 3ATA for 48 h, and protein expression was measured
using ﬂow cytometry (Fig. 2B) and conﬁrmed by western blotting
(Fig. 2C). The results obtained using both analyses showed no
alteration in protein expression after 48 h of 3ATA treatment.
Similar results were obtained using cytometry after 72 h of
treatment with 3ATA (data not shown).
3.2. 3ATA sensitizes MRP1/ABCC1-overexpressing cells to
antitumoral drugs
GLC4/ADR is resistant to several chemotherapeutic drugs,
including doxorubicin (DOX) and vincristine (VCR) (de Groot
et al., 2007; van der Graaf et al., 1994). To evaluate whether the
inhibition of MRP1/ABCC1 by 3ATA sensitizes GLC4/ADR to anti-
neoplastic drugs, cells were co-incubated for 48 h with increasing
concentrations of DOX, VCR or cisplatin (CIS) in the presence or
absence of 25 mg/ml 3ATA and cell viability was measured by MTT.
At this concentration, 3ATA is not toxic (Fig. 2A) but modulates the
activity of MRP1/ABCC1 (Fig. 2D and F). Fig. 3 shows that 3ATA
sensitizes GLC4/ADR to VCR and DOX, drugs that are transported
by MRP1/ABCC1 (Fig. 3A and B) but did not interfere with cisplatin
cytotoxicity (Fig. 3C). Indeed co-treatment of cells with 3ATA and
50 mM DOX or 12.5 nM VCR induces about 2.5 and 2.3 times
decrease in cell viability, respectively (Fig. 3A and B). To further
characterize the relationship between the sensitizing effect of
3ATA and MRP1/ABCC1 expression, GLC4 cells (the parental
GLC4/ADR cell line, which expresses low levels of MRP1/ABCC1)
were treated with 3ATA in the presence of DOX or VCR, and cell
viability was measured using MTT. Because GLC4 is more sensitive
than GLC4/ADR, we used doses of DOX and VCR ranging between
Fig. 2. 3ATA decreases the viability of GLC4/ADR cells and inhibits the activity of MRP1/ABCC1 but does not modulate its expression. (A) Cell viability: cells were treated with
various concentrations of 3ATA, and the viability was assessed 48 h later using MTT. (B,C) Levels of MRP1/ABCC1 expression: MRP1/ABCC1 expression in cells untreated or
treated for 48 h with 3ATA were measured using ﬂow cytometry and presented as representative histograms and arbitrary units of mean ﬂuorescence intensity (B) or, by
western blotting (C). (D,F) MRP1/ABCC1 activity: cells were incubated for 30 min with 5 μM CFDA in the presence of medium (C), 50 μM MK-571 (MK50) or the indicated
concentrations of 3ATA, and the intracellular ﬂuorescence was evaluated using ﬂow cytometry. The results are expressed as representative histograms (D) and in arbitrary
units of mean ﬂuorescence intensity (E). Cells were also incubated with 3ATA for 24 or 48 h before addition of CFDA (F). The data in all ﬁgures are presented as the means7S.
D. of at least 3 experiments. nPo0.05 and nnPo0.01 indicate values signiﬁcantly different from non-treated cells (C).
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2–8 mM and 1–4 nM, respectively, in this assay. The results indicated
that 3ATA did not affect the cytotoxicity of DOX or VCR in this cell
line (Fig. 3D and E).
To get some insights into the deathmechanisms induced by the co-
treatment, cells were treated for 48 h with medium, 25 mg/ml 3ATA,
50 mM DOX, 12.5 nM VCR or a combination of 3ATA and DOX or VCR
and DNA fragmentation was assessed by quantiﬁcation of the subG1
peak of the of the cell cycle (Fig. 4A) that was considered apoptotic.
The signiﬁcant increase in DNA fragmentation shownwhen cells were
co-treated with 3ATA and DOX (3.8 ) or 3ATA and VCR (9.3 )
(Fig. 4B) indicates that 3ATA is sensitizing the cells to the chemothera-
pics, leading to a synergistic response. In order to clarify the mechan-
isms of death induced by the co-treatment, cell death was analyzed by
Annexin V – FITC/PI and the amount of necrotic and apoptotic cells
was determined. The results demonstrated that although the co-
treatment induced some necrosis, apoptosis is the major mechanism
of death (Fig. 4C).
3.3. 3ATA modulates total intracellular GSH levels, GST activity
and Reactive Oxygen Species levels in MRP1/ABCC1 expressing cells
Because 3ATA was able to sensitize MRP1/ABCC1 expressing
cells to drugs, the transport of which is GSH dependent, it was of
interest to assess the effect of 3ATA on GSH levels in this cell line.
For this, cells were treated with medium, 25 or 50 mg/ml 3ATA, or
500 mM BSO for 48 h, and GSH levels were determined using a kit
based on the enzymatic recycling of oxidized glutathione (GSSG)
reductase using the 2-nitro-5-thiobenzoic acid (DTNB) reagent as
described in Section 2. As shown in Fig. 5A, 48 h of exposure to
3ATA caused dose-dependent reductions in the total glutathione
pools of this MDR cell line. At 25 mg/ml 3ATA (concentration used
in reversal assays), GSH levels were reduced by approximately 50%
compared to the control, whereas at higher concentration (50 mg/ml),
the decrease was similar to that observed for BSO, an inhibitor of GSH
synthesis.
Fig. 3. 3ATA modulates the sensitivity of an MDR cell line to antitumoral drugs. GLC4/ADR cells were co-incubated for 48 h with 25 mg/ml of 3ATA and the indicated
concentrations of (A) vincristine (VCR), (B) doxorubicin (DOX) or (C) cisplatin (CIS). Similarly, GLC4 cells were co-incubated with 12.5 mg/ml 3ATA and various concentrations
of DOX (D) and VCR (E). Cell viability was assessed using MTT. The results show the means7SD of at least 3 experiments performed in triplicate. nPo0.05 and nnPo0.01
indicate signiﬁcant differences from treatment with conventional drugs and drugs plus 3ATA.
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Fig. 4. 3ATA increases apoptotic cell death induced by DOX and VCR. GLC4/ADR cells were incubated for 48 h with medium, 25 mg/ml of 3ATA, 50 mM of DOX, 12.5 nM of VCR
or, co-incubated with 3ATA and DOX or 3ATA and VCR and DNA fragmentation quantiﬁed by measuring the subG1 peak of the cell cycle. Alternatively cells were incubated
with annexin V-FITC/PI and cell death were assessed by cytometry. The results are presented as representative histograms (A) and means7S.D. of % DNA fragmentation
(B) or percentage of apoptotic and necrotic cells (C). (nn) indicates values that are signiﬁcantly different (Po0.01) between cells treated with drugs alone or co-treated
with 3ATA.
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Considering the involvement of GSTs in the transport of GSH-
conjugated drugs (Brechbuhl et al., 2012), we analyzed the effect
of 3ATA on GST activity. Cells were treated with 3ATA for 24 h with
12.5, 25 or 50 mg/ml of 3ATA, and the resulting GST activity was
measured using a colorimetric assay kit (BioVision) based upon
the GST-catalyzed reaction between GSH and the GST substrate,
CDNB (1-chloro-2,4-dinitrobenzene) as described in Section 2. The
results shown in Fig. 5B demonstrate that cells exposed to 3ATA
for 24 h exhibited signiﬁcant dose-dependent decreases in GST
activity. At 25 mg/ml, 3ATA decreased GST activity to approximately
60% of the control value.
Depletion of cellular GSH pools is thought to increase oxidative
stress and, depending on the intensity of this depletion, may lead
to cell death (Trachootham et al., 2009). Because 3ATA is able to
decrease glutathione pools in GLC4/ADR cells, we evaluated
whether treatment with this triterpene would also interfere with
the levels of Reactive Oxygen Species. Cells were treated with
medium or various concentrations of 3ATA (6.25; 12.5 and 25 mg/ml)
for 24 or 48 h, and intracellular Reactive Oxygen Species levels were
determined by ﬂow cytometry using H2DCFDA. Fig. 5C and D shows
that cellular Reactive Oxygen Species increased after exposure to
increasing concentrations of 3ATA for 24 h. Similar results were
obtained after 48 h incubation (data not shown).
4. Discussion
In an attempt to circumvent MDR and improve the efﬁcacy of
cancer treatment, several strategies have been elaborated (Wu
et al., 2011), including inhibition of the activity of MDR proteins
(one of the most explored methods). Pharmacological inhibition of
MRP1/ABCC1 activity has been hampered by the lack of speciﬁc
inhibitors; most inhibitors also block P-gp/ABCB1 activity (Shukla
et al., 2011). Previous studies conducted by our group have
demonstrated that 3ATA does not affect Pgp/ABCB1 activity
(Rocha et al., 2012a) but does modulate the activity of MRP1/
ABCC1 in melanoma and non-small cell lung cancer cell lines
(Rocha et al., 2012b). In this study, we used GLC4/ADR, a MRP1-
overexpressing small cell lung cancer cell line, to investigate anti-
MRP1/ABCC1 mechanisms mediated by this triterpene and to
analyze its ability to revert MDR.
In cancer, any compound that has the potential to become an
inhibitor of an ABC transporter should be capable of sensitizing
MDR cells to the antineoplastic drugs that are substrates for the
transporter proteins. MDR resistance may be overcome by very
high and toxic concentration of substrate drugs. GLC4/ADR is
resistant to several types of cancer chemotherapics including
anthracyclines, vinca alkaloids and etoposide, but not to cisplatin.
The data reported in this paper show that treatment of GLC4/ADR
with a non-toxic concentration of 3ATA (25 mg/ml) increased its
sensitivity to the cytotoxic effects of two drugs extensively used in
cancer treatment, doxorubicin and vincristine. This effect appears
to be related to MRP1/ABCC1 overexpression in GLC4/ADR and was
not observed in the parental GLC4 cells. Indeed, other investigators
have previously described the ability of MRP1/ABCC1 inhibitors to
sensitize resistant cells to antineoplastic drugs (Garrido et al.,
2011; van Zanden et al., 2005; Benyahia et al., 2004), but the
mechanisms of this effect are still not well understood. It is known
that MRP1/ABCC1 inhibitors such as piperine (Li et al., 2011) are
capable of modulating the expression of this transporter, leading
to reversal of MDR in cells expressing MRP. However, in this paper,
the evaluation of MRP1/ABCC1 expression using ﬂow cytometry
Fig. 5. 3ATA modulates the levels of total intracellular GSH, GST activity and ROS in GLC4/ADR cells. (A) Determination of intracellular GSH. Cells were incubated with
medium, 500 mM BSO or 3ATA for 48 h, and the levels of total glutathione were estimated in the cell lysates using a GSH determination kit (BioVision). (B) GST activity. Cells
were incubated with medium or various concentrations of 3ATA for 24 h, and the GST activity in cell lysates was estimated using a commercial kit (BioVision). (C,D)
Determination of ROS. Cells were incubated for 24 h with medium (C) and the desired concentrations of 3ATA; the cells were then treated with H2DCFDA, and the
intracellular ﬂuorescence, which is indicative of ROS levels, was evaluated using cytometry. Results were presented as representative histograms shown in (C) or in arbitrary
units of mean ﬂuorescence intensity (D). The data in all ﬁgures represent the means7S.D. of at least 3 experiments. nPo0.05 and nnPo0.01 indicate values signiﬁcantly
different from non-treated cells (C).
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and western blotting showed that 3ATA does not modulate the
expression of this protein; this ﬁnding indicates that the reversal
of drug resistance by 3ATA likely results from interference in
protein transport activity. Thus, it is possible that the reversal
effect of 3ATA may signiﬁcantly impact cancer treatment by
allowing the use of smaller treatment doses, and resulting in
better patient tolerance and compliance. Interestingly, 3ATA did
not sensitize GLC4/ADR to cisplatin, a drug that does not seem to
be a substrate for MRP1 or to induce resistance to this protein
(Borst et al., 2000).
The mechanism of transport by MRP1/ABCC1 is very complex.
This protein is able to transport a wide array of physiological and
exogenous substrates, including several antineoplastic drugs,
either conjugated or not conjugated with glutathione (GSH),
glucuronide or sulfate (Deeley et al., 2006; Chen and Tiwari,
2011). Because tumor cells are very sensitive to variations in GSH
levels, this molecule has been targeted in new approaches to
sensitize cancer cells to chemotherapy. Thus, combining the use of
chemotherapeutics with compounds that are able to inhibit GSH
synthesis or its turnover could be a possible strategy to bypass
MDR in cancer cells; data reported in the literature data have
shown that the transport of DOX and VCR, which is mediated by
MRP1/ABCC1, is GSH-dependent and therefore might be inﬂu-
enced by the intracellular GSH pool or by GST activity (Deeley
et al., 2006; Sau et al., 2010).
The GSTs are classical phase II metabolic enzymes that detoxify
xenobiotics via the conjugation of reduced GSH with a wide
variety of hydrophilic molecules. Due to their ability to metabolize
both carcinogens and cancer chemotherapeutics, GSTs might play
an important role in cancer susceptibility, the development of
chemoresistance, and clinical outcome (Board and Menon, 2013).
It has been described that GSH conjugates of alkylating agents,
which are produced by GSTs, are less active than their parent
compounds and are exported from cells by transporters (Colvin
et al., 1993). This paper showed that 25 mg/ml 3ATA was able to
reduce in approximately 50% of the total GSH levels in MDR tumor
cells while at 50 mg/ml its effect is similar to that observed with
BSO, decreasing the GSH pool to about 20%. Interestingly, 3ATA
also inhibits GST activity. Treatment with 25 or 50 mg/ml 3 ATA
leads to a 50% and 80% decrease in GST activity, respectively.
Taken together, the results show that 3ATA induces decreases
in GSH levels and GST activity, suggesting that the effect of this
triterpene on the sensitization of the MRP1/ABCC1-resistant cell
line to doxorubicin may be mediated by its actions on these
pathways. These results are consistent with previously published
data showing that the inhibitory effects of indomethacin, ﬂavo-
noids and gallic acid on MRP1/ABCC1 activity results from their
interference with the GSH pool (Asano et al., 2009; Leslie et al.,
2003; You and Park, 2010). Moreover, it has been described that
other compounds, such as ethacrynic acid (Zaman et al., 1996),
which inhibits GST, can also overcome MDR because the conjuga-
tion of xenobiotics with GSH is affected in this process.
Drug-resistant cells that overexpress MRP1/ABCC1 and/or GST
also have an elevated intracellular pool of GSH (van Brussel et al.,
2004; Takemura et al. 2001; Gallego et al., 2004). In these cells,
GSH plays an important role both in the MRP1/ABCC1 transport of
drugs and in the homeostasis of cellular redox status. Since, GSH is
a key molecule of the cells antioxidant systems, keeping the
homeostasis of the redox state of cells, GSH forms part of the
defense against Reactive Oxygen Species (ROS). Thus, a decrease in
the levels of this molecule may lead to intrinsic oxidative stress
and the accumulation of Reactive Oxygen Species (ROS), which
have been shown to cause cell death in various tumor model
systems (Trachootham et al., 2009). Alteration of metabolic path-
ways leading to formation of Reactive Oxygen Species was also
shown to sensitize resistant tumor cells to chemotherapeutic
drugs (Marra et al., 2008). The results obtained in this study
showing that 3ATA is able to increase the levels of Reactive Oxygen
Species in GLC4/ADR might reﬂect its effect on the intracellular
GSH pool.
In a previous paper we showed that 3ATA inhibits the activity
of ABCC/MRP transporters being more effective for MRP1 (Rocha
et al., 2012b). Data presented in this paper show that 3β-acetyl
tormentic acid (3ATA) sensitizes cells that over expressed ABCC1/
MRP1 to the cytotoxic effects of DOX and VCR, drugs which
transport is dependent on GSH. Interestingly, 3ATA had no effect
of the cytoxicity of cisplatin in GLC4/ADR, a cell line that does not
show resistance to this drug (Berger et al., 1997). In fact, expres-
sion of MRP1 does not necessarily confer resistance to cisplatin as
cells transfected with MRP1 do not show cisplatin resistance (Cole
et al., 1994). In addition, although the dependence of cisplatin
cytotoxicity on intracellular GSH is well known and cisplatin-
resistant cells have increased levels of GSH, its depletion did not
always affect cellular resistance showing that modulation of
cisplatin resistance may involve other mechanisms than GSH (Lai
et al., 1995; Stordal and Davey, 2007).
The data in this paper also suggest that 3ATA may potentiate
cancer therapies for GSH-dependent substrates. Fig. 6 summarizes
the possible mechanisms involved in this effect. (1) By inhibiting
the MRP1 activity, 3ATA increases the intracellular pool of drug
allowing it to reach effective cytotoxic/lethal concentration.
(2) This effect is also due to the ability of 3ATA in inhibiting GST
activity and therefore, decreasing the amount of conjugated drug
to be transported. (3) 3ATA decreases the intracellular pool of GSH
contributing to limit the availability of cellular GSH needed for
metabolizing and transporting some alkylating agents out of the
cell. (4) By affecting/altering the GSH pool, 3ATA also decreases the
antioxidant capacity of the cell and favors Reactive Oxygen Species
accumulation. The overall result of these mechanisms is increased
accumulation of drugs and cell death.
In addition to reinforcing previous observations on the MRP1/
ABCC1-modulatory effects of 3ATA, the data presented in this
paper enabled identiﬁcation of some of the mechanisms involved
in this effect and showed that 3ATA is also able to sensitize
Fig. 6. Mechanisms involved in sensitization of cancer cells by 3ATA. (1) By
inhibiting the MRP1 activity, 3ATA increases the intracellular pool of drug allowing
it to reach effective cytotoxic/lethal concentration. (2) This effect is also due to the
ability of 3ATA in inhibiting GST activity and therefore, decreasing the amount of
conjugated drug to be transported. (3) 3ATA decreases the intracellular pool of GSH
contributing to limit the availability of cellular GSH needed for metabolizing and
transporting some alkylating agents out of the cell. (4) By affecting/altering the GSH
pool, 3ATA also decreases the antioxidant capacity of the cell, favors ROS
accumulation. The overall result of these mechanisms is increased accumulation
of drugs and cell death.
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MDR-cells to antineoplastic drugs, the transport of which depends
on GSH conjugation. Our data are also consistent with the proposal
that the utilization of compounds that are able to interfere with
the MRP/GST/GSH-molecular cascade that leads to decreases in
the cellular GSH pool may impair the drug efﬂux machinery, with
a concomitant rise in the sensitivity of drug-resistant cells to
antineoplastic agents. Thus, 3ATA is a promising MRP1/ABCC1
inhibitor that could be used to ﬁght drug resistance in cancer and
in other diseases where resistance is related to elevated glu-
tathione levels.
5. Conclusions
3ATA increased the sensitivity of MRP1-overexpressing cells to
doxorubicin and vincristine without signiﬁcant changes in MRP1
expression levels. 3ATA was also able to decrease both the pool of
total intracellular glutathione, glutathione-s-transferase activity
and Reactive Oxygen Species levels indicating a possible mechan-
ism for the GLC4/ADR sensitization mediated by 3ATA. The co-
administration of 3ATA may be useful for treatment of patients
presenting resistant tumors.
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